For Cytokinetics Incorporated [CYTK], Raymond James sees a rise to $39. What next?

Must read

Cytokinetics Incorporated [NASDAQ: CYTK] traded at a high on 08/20/20, posting a 3.77 gain after which it closed the day’ session at $24.21. The company report on August 18, 2020 that Cytokinetics Announces Partnership to Improve Prediction of Risk and Outcomes in Hypertrophic Cardiomyopathy.

Company Makes Long-term Commitment to Outcomes Research in HCM.

Cytokinetics, Incorporated (Nasdaq:CYTK) today announced a $1 million grant and four-year partnership with the HCM Registry (HCMR), a global registry of patients with hypertrophic cardiomyopathy (HCM) focused on improving predictive measures of risk for complications and identifying biomarkers associated with adverse clinical outcomes. The HCMR was designed as the first prospective multinational registry to identify novel prognostic markers in HCM, including CMR markers of fibrosis, genetic markers, and biomarkers. It has been funded to date by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (Grant number: U01 HL117006-01A1) and is being conducted by the University of Virginia and the University of Oxford. As an industry sponsor, Cytokinetics will join the HCMR Steering Committee in an observational capacity.

The results of the trading session contributed to over 1049710 shares changing hands. Over the past one week, the price volatility of Cytokinetics Incorporated stands at 4.36% while the volatility over the past one month is 4.77%.

The market cap for CYTK stock reached $1.73 billion, with 70.50 million shares outstanding and 62.43 million shares in the current float. Compared to the average trading volume of 844.91K shares, CYTK reached a trading volume of 1049710 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Cytokinetics Incorporated [CYTK]?

Raymond James have made an estimate for Cytokinetics Incorporated shares, keeping their opinion on the stock as Strong Buy, with their previous recommendation back on July 10, 2020. While these analysts kept the previous recommendation, Mizuho raised their target price to Buy. The new note on the price target was released on May 05, 2020, representing the official price target for Cytokinetics Incorporated stock. Previously, the target price had yet another raise to $25, while Morgan Stanley analysts kept a Overweight rating on CYTK stock.

The Average True Range (ATR) for Cytokinetics Incorporated is set at 1.29, with the Price to Sales ratio for CYTK stock in the period of the last 12 months amounting to 92.62.

How has CYTK stock performed recently?

Cytokinetics Incorporated [CYTK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.95. With this latest performance, CYTK shares gained by 1.36% in over the last four-week period, additionally plugging by 58.44% over the last 6 months – not to mention a rise of 73.67% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CYTK stock in for the last two-week period is set at 55.43, with the RSI for the last a single of trading hit 60.69, and the three-weeks RSI is set at 54.42 for Cytokinetics Incorporated [CYTK]. The present Moving Average for the last 50 days of trading for this stock 23.63, while it was recorded at 23.51 for the last single week of trading, and 16.02 for the last 200 days.

Cytokinetics Incorporated [CYTK]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Cytokinetics Incorporated [CYTK] shares currently have an operating margin of -367.97. Cytokinetics Incorporated’s Net Margin is presently recorded at -452.93.

Return on Total Capital for CYTK is now -102.20, given the latest momentum, and Return on Invested Capital for the company is -130.67. Return on Equity for this stock declined to -1,622.88, with Return on Assets sitting at -48.58. Additionally, CYTK Total Debt to Total Capital is recorded at 108.74, with Total Debt to Total Assets ending up at 46.95.

Reflecting on the efficiency of the workforce at the company, Cytokinetics Incorporated [CYTK] managed to generate an average of -$780,077 per employee. Receivables Turnover for the company is 4.50 with a Total Asset Turnover recorded at a value of 0.11.Cytokinetics Incorporated’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.60 and a Current Ratio set at 9.60.

Earnings analysis for Cytokinetics Incorporated [CYTK]

With the latest financial reports released by the company, Cytokinetics Incorporated posted -0.5/share EPS, while the average EPS was predicted by analysts to be reported at -0.49/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -2.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CYTK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Cytokinetics Incorporated go to 15.00%.

Insider trade positions for Cytokinetics Incorporated [CYTK]

There are presently around $1,361 million, or 81.80% of CYTK stock, in the hands of institutional investors. The top three institutional holders of CYTK stocks are: BLACKROCK INC. with ownership of 9,361,689, which is approximately 2.592% of the company’s market cap and around 1.10% of the total institutional ownership; VANGUARD GROUP INC, holding 4,571,208 shares of the stock with an approximate value of $110.67 million in CYTK stocks shares; and FMR LLC, currently with $84.95 million in CYTK stock with ownership of nearly 19.654% of the company’s market capitalization.

89 institutional holders increased their position in Cytokinetics Incorporated [NASDAQ:CYTK] by around 9,258,640 shares. Additionally, 69 investors decreased positions by around 8,429,197 shares, while 24 investors held positions by with 38,543,164 shares. The mentioned changes placed institutional holdings at 56,231,001 shares, according to the latest SEC report filing. CYTK stock had 29 new institutional investments in for a total of 4,806,708 shares, while 19 institutional investors sold positions of 4,549,753 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam